sunitinib rowex 50 mg hard capsules
rowex ltd - sunitinib - capsule, hard - 50 milligram(s) - protein kinase inhibitors; sunitinib
sunitinib sandoz 12.5 mg hard caps.
sandoz sa-nv - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib
sunitinib sandoz 25 mg hard caps.
sandoz sa-nv - sunitinib 25 mg - capsule, hard - 25 mg - sunitinib 25 mg - sunitinib
sunitinib sandoz 50 mg hard caps.
sandoz sa-nv - sunitinib 50 mg - capsule, hard - 50 mg - sunitinib 50 mg - sunitinib
sunitinib teva 12.5 mg hard caps.
teva b.v. - sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib 12.5 mg - sunitinib
sunitinib teva 25 mg hard caps.
teva b.v. - sunitinib 25 mg - capsule, hard - 25 mg - sunitinib 25 mg - sunitinib
sunitinib teva 37.5 mg hard caps.
teva b.v. - sunitinib 37,5 mg - capsule, hard - 37,5 mg - sunitinib 37.5 mg - sunitinib
sunitinib teva 50 mg hard caps.
teva b.v. - sunitinib 50 mg - capsule, hard - 50 mg - sunitinib 50 mg - sunitinib
sunitinib malate capsule
sun pharmaceutical industries inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregn
sunitinib krka 12.5 mg hard caps.
krka d.d. novo mesto d.d. - sunitinib malate 16,71 mg - eq. sunitinib 12,5 mg - capsule, hard - 12,5 mg - sunitinib malate 16.71 mg - sunitinib